DOI QR코드

DOI QR Code

Application of MMP-7 and MMP-10 in Assisting the Diagnosis of Malignant Pleural Effusion

  • Cheng, Daye (Department of Transfusion, The First Hospital of China Medical University) ;
  • Liang, Bin (High Vocational Technological College, China Medical University) ;
  • Li, Yun-Hui (Department of Clinical Laboratory, No. 202 Hospital, Shenyang)
  • Published : 2012.02.29

Abstract

Background: Matrix metalloproteinases (MMP) are proteolytic enzymes that are essentially involved in turnover of the extracellular matrix (ECM). The aim was to investigate the diagnostic value of MMP-7 and MMP-10 as tumor markers in pleural effusion (PE) and evaluate the value of combining MMP-7, MMP-10 and carcinoembryonic antigen (CEA) assays as diagnostic aids for malignant cells. Materials and Methods: A total of 179 patients with PE (87 malignant and 92 benign) were included in this study. The levels of MMP-7 and MMP-10 were measured using ELISA. Results: Values for MMP-7 and MMP-10 were significantly higher in malignant PE than those in benign PE (P<0.01). Among all variables evaluated, logistic regression found that MMP-7 and MMP-10 were significantly correlated with the presence of malignant disease (P<0.01). Analysis of receiver operating characteristics (ROC) curves showed that the area under the curve of MMP-10 (0.806) was significantly larger than that of MMP-7 (0.771) and CEA (0.789) (P<0.01). With parallel interpretation, the combination of MMP-10 and CEA achieved the higher sensitivity of 94.6%. The combination of MMP-7 and CEA in serial interpretation was able to boost the specificity to 95.7%. The combination of MMP-7, MMP-10 and CEA produced better sensitivity, specificity, PPV and NPV than MMP-7 and MMP-10 alone. Conclusion: MMP-7 and MMP-10 in PE may represent helpful adjuncts to conventional diagnostic tools in ruling out malignancy as a probable diagnosis, thus guiding the selection of patients who might benefit from further invasive procedures.

Keywords

Matrix metalloproteinases;pleural effusion;diagnosis;cancer

References

  1. Aung PP, Oue N, Mitani Y, et al (2006). Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene, 25, 2546-57. https://doi.org/10.1038/sj.onc.1209279
  2. Beeghly-Fadiel A, Shu XO, Long J, et al (2009). Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int J Cancer, 124, 208-14. https://doi.org/10.1002/ijc.23859
  3. Birkedal-Hansen B, Pavelic ZP, Gluckman JL, et al (2000). MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Diseases, 6, 376-82.
  4. Bodey B, Bodey B, Jr Siegel SE, et al (2001). Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas. Anticancer Research, 21, 2021-8.
  5. Dekker A, Bupp PA (1976). Cytology of serous effusions: a comparative study of two slightly different preparative methods. Acta Cytologica, 20, 394-9.
  6. Fenton KN, Richardson JD (1995). Diagnosis and management of malignant pleural effusions. Am J Surgery, 170, 69-74. https://doi.org/10.1016/S0002-9610(99)80257-8
  7. Fiorelli A, Vicidomini G, Di Domenico M, et al (2011). Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interat Cardiovasc Thorac Surg, 12, 420-4. https://doi.org/10.1510/icvts.2010.250357
  8. Garcia-Pachon E, Padilla-Navas I, Dosda MD, et al (1997). Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest, 111, 643-7. https://doi.org/10.1378/chest.111.3.643
  9. Kerkela E, Ala-aho R, Lohi J, et al (2001). Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer, 84, 659-69. https://doi.org/10.1054/bjoc.2000.1634
  10. Liu H, Zhang T, Li X, et al (2008). Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci 99, 2185-92. https://doi.org/10.1111/j.1349-7006.2008.00922.x
  11. Mathew R, Khanna R, Kumar R, et al (2002). Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect Prev, 26, 222-8. https://doi.org/10.1016/S0361-090X(02)00035-1
  12. Miserocchi G (1997). Physiology and pathophysiology of pleural fluid turnover. Eur Respir J, 10, 219-25. https://doi.org/10.1183/09031936.97.10010219
  13. Monte SA, Ehya H, Lang WR (1987). Positive effusion cytology as the initial presentation of malignancy. Acta Cytol, 31, 448-52.
  14. Nagase H, Woessner JF Jr (1999). Matrix metalloproteinases. J Biol Chem, 274, 21491-4. https://doi.org/10.1074/jbc.274.31.21491
  15. Nelson AR, Fingleton B, Rothenberg ML, et al (2000). Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 18, 1135-49. https://doi.org/10.1200/JCO.2000.18.5.1135
  16. Newell KJ, Witty JP, Rodgers WH, et al (1994). Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Molec Carcinogenesis, 10, 199-206. https://doi.org/10.1002/mc.2940100404
  17. Paganuzzi M, Onetto M, Marroni P, et al (2001). Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest, 119, 1138-42. https://doi.org/10.1378/chest.119.4.1138
  18. Porcel JM, Vives M, Esquerda A, et al (2004). Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest, 126, 1757-63. https://doi.org/10.1378/chest.126.6.1757
  19. Riantawan P, Sangsayan P, Bangpattanasiri K, et al (2000). Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion. Respiration, 67, 24-9. https://doi.org/10.1159/000029458
  20. Ries C, Petrides PE (1995). Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe-Seyler, 376, 345-55.
  21. Rittgers RA, Loewenstein MS, Feinerman AE, et al (1978). Carcinoembryonic antigen levels in benign and malignant pleural effusions. Ann Intern Med, 88, 631-4. https://doi.org/10.7326/0003-4819-88-5-631
  22. Romero S, Fernandez C, Arriero JM, et al (1996). CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J, 9, 17-23. https://doi.org/10.1183/09031936.96.09010017
  23. Safranek J, Pesta M, Holubec L, et al (2009). Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Research, 29, 2513-7.
  24. Sahn SA (1988). State of the art. The pleura. Am Rev Respir Dis, 138, 184-234. https://doi.org/10.1164/ajrccm/138.1.184
  25. Seargent JM, Loadman PM, Martin SW, et al (2005). Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology, 65, 815-20. https://doi.org/10.1016/j.urology.2004.11.016
  26. Shi M, Liu D, Duan H, et al (2010). Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Molec Cancer, 9, 269.
  27. Shiomi T, Okada Y (2003). MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev, 22, 145-52. https://doi.org/10.1023/A:1023039230052
  28. Sounni NE, Noel A (2005). Membrane type-matrix metalloproteinases and tumor progression. Biochimie, 87, 329-42. https://doi.org/10.1016/j.biochi.2004.07.012
  29. Szarvas T, Jager T, Becker M, et al (2011). Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res, 17, 325-32. https://doi.org/10.1007/s12253-010-9320-4
  30. Van de Molengraft FJ, Vooijs GP (1989). Survival of patients with malignancy-associated effusions. Acta Cytol, 33, 911-6.
  31. Wasenius VM, Hemmer S, Kettunen E, et al (2003). Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are upregulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res, 9, 68-75.
  32. Wobbes T, Thomas CM, Segers MF, et al (1992). Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer, 69, 2036-41. https://doi.org/10.1002/1097-0142(19920415)69:8<2036::AID-CNCR2820690805>3.0.CO;2-M
  33. Woessner JF Jr (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J, 5, 2145-54. https://doi.org/10.1096/fasebj.5.8.1850705

Cited by

  1. Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer vol.18, pp.5, 2013, https://doi.org/10.3109/1354750X.2013.797499
  2. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in malignant pleural effusion in patients with lung cancer vol.11, pp.1, 2014, https://doi.org/10.1111/ajco.12195
  3. Utility of Nuclear Morphometry in Effusion Cytology vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6919
  4. Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1220-2
  5. Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer vol.36, pp.6, 2015, https://doi.org/10.1007/s13277-015-3079-x
  6. Association of matrix metalloproteinase-10 polymorphisms with susceptibility to pelvic organ prolapse vol.41, pp.12, 2015, https://doi.org/10.1111/jog.12809
  7. Reactive oxygen species modulator 1, a novel protein, combined with carcinoembryonic antigen in differentiating malignant from benign pleural effusion vol.39, pp.5, 2017, https://doi.org/10.1177/1010428317698378